Acupuncture for Patients With Major Depressive Disorder

Sponsor
Chengdu University of Traditional Chinese Medicine (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05106868
Collaborator
(none)
123
3
19.9

Study Details

Study Description

Brief Summary

Several studies investigating acupuncture for major depressive disorder (MDD) have been carried out. However, investigators found the results were in high heterogeneity and poor methodological quality. Thus, investigators intend to provide high quality of the effectiveness and safety of acupuncture for MDD.

Condition or Disease Intervention/Treatment Phase
  • Device: acupuncture
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
123 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Acupuncture for Patients With Major Depressive Disorder: Study Protocol of a Randomized Controlled Trial
Anticipated Study Start Date :
Nov 1, 2021
Anticipated Primary Completion Date :
Dec 30, 2022
Anticipated Study Completion Date :
Jun 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: acupuncture

5 sessions of acupuncture per week for 4 weeks. In each session, acupuncture will be applied bilaterally on acupoints. We will use transcutaneous electric acupoints stimulation (HANS; Han's acupoints nerve stimulator, HANS-200, Nanjing, China) to stimulate the acupoints. Each session will last 30 minutes.

Device: acupuncture
Acupuncture is a form of alternative medicine and a component of traditional Chinese medicine (TCM) in which thin needles are inserted into the acupoints on body to treat diseases.

Sham Comparator: sham acupuncture

5 sessions of sham acupuncture per week for 4 weeks. In each session, acupuncture will be applied bilaterally on non-acupoints. We will use transcutaneous electric acupoints stimulation (HANS; Han's acupoints nerve stimulator, HANS-200, Nanjing, China) to stimulate the non-acupoints. Each session will last 30 minutes.

Device: acupuncture
Acupuncture is a form of alternative medicine and a component of traditional Chinese medicine (TCM) in which thin needles are inserted into the acupoints on body to treat diseases.

No Intervention: waiting-list

Outcome Measures

Primary Outcome Measures

  1. score of Hamilton Depression Rating Scale-24 [change from baseline to 4 weeks after intervention, after follow-up(4 week)]

    Reduction in the severity of depression, measured at the end of the intervention primarily as a continuous variable on the Hamilton Depression Rating Scale (HAMD)-24

Secondary Outcome Measures

  1. score of self-rating depression scale [baseline, after intervention(4 week), after follow-up(4 week)]

    Reduction in the severity of depression, measured at the end of the intervention primarily as a continuous variable on self-rating depression scale (SDS)

  2. score of Hamilton Anxiety Rating Scale [baseline, after intervention(4 week) , after follow-up(4 week)]

    Reduction in the severity of depression, measured at the end of the intervention primarily as a continuous variable on Hamilton Anxiety Rating Scale (HAMA)

  3. score of Social Disability Screening Schedule [baseline, after intervention(4 week) , after follow-up(4 week)]

    change of score of Social Disability Screening Schedule (SDSS)

  4. score of Pittsburgh sleep quality index (PSQI) [baseline, after intervention(4 week) , after follow-up(4 week)]

    change of score of Pittsburgh sleep quality index (PSQI)

  5. motor threshold (MT) [baseline, after intervention(4 week) , after follow-up(4 week)]

    motor threshold (MT) measured by Brain Ultimate Combined with MEB-2312 EMG/evoked potentiometer

  6. Intra-cortical facilitation (ICF) [baseline, after intervention(4 week) , after follow-up(4 week)]

    Intra-cortical facilitation (ICF) measured by Brain Ultimate Combined with MEB-2312 EMG/evoked potentiometer

  7. cortical resting period (CSP) [baseline, after intervention(4 week) , after follow-up(4 week)]

    cortical resting period (CSP) measured by Brain Ultimate Combined with MEB-2312 EMG/evoked potentiometer [Time Frame: baseline, after intervention(4 week), after follow-up(4 week)]

  8. intra-cortical inhibition (ICI) [baseline, after intervention(4 week) , after follow-up(4 week)]

    intra-cortical inhibition (ICI) measured by Brain Ultimate Combined with MEB-2312 EMG/evoked potentiometer

  9. IAPS Evoked Event-related Potentials (ERP) [baseline, after intervention(4 week), after follow-up(4 week)]

    IAPS Evoked Event-related Potentials (ERP)

  10. Evoked Event-related Potentials (ERP) in TMS-EEG [baseline, after intervention(4 week), after follow-up(4 week)]

    Evoked Event-related Potentials (ERP) in TMS-EEG

  11. Adverse events [during intervention(4 week)]

    Adverse events

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. Right-handed participants aged between 18 to 60 years;

  2. participants diagnosed with mild to moderate major depressive disorder(MDD), and meet the diagnostic criteria of mild to moderate MDD according to the Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition (DSM-5);

  3. participants with score of HAMD-24 between 8 to 35;

  4. participants without anti-depressive medication more than 3 months;

  5. participants willing to comply with the study protocol;

  6. participants willing to sign informed consent form.

Exclusion Criteria:
  1. participants with severe medical visceral condition and chronic diseases, such as hypertension, coronary heart disease, hyperthyroidism, hypothyroidism or diabetes and other endocrine system diseases;

  2. participants with brain organic diseases: such as birth injury, trauma, encephalitis, tumor, etc.;

  3. participants with Peripheral nerve and muscular system diseases;

  4. participants with severe anxiety, obsessive-compulsive disorder, or a history of mania or hypomania;

  5. Recently taken drugs that may cause mood disorders;

  6. Severe bleeding tendency, allergic constitution and skin disease patients;

  7. pregnant or lactation women;

  8. Persons with visual and hearing disabilities;

  9. Participants with pacemakers, deep brain stimulators, vagus nerve stimulators, metal internal fixators, etc

  10. participate in other clinical trials at the same time

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Chengdu University of Traditional Chinese Medicine

Investigators

  • Study Chair: Jian Huang, Institute of Science and Technology Development, Sichuan University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Di Qin, Professor, Chengdu University of Traditional Chinese Medicine
ClinicalTrials.gov Identifier:
NCT05106868
Other Study ID Numbers:
  • 2019-1273
First Posted:
Nov 4, 2021
Last Update Posted:
Nov 4, 2021
Last Verified:
Oct 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Di Qin, Professor, Chengdu University of Traditional Chinese Medicine
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 4, 2021